Industry News
UK hints at end to drug price controls
The British government said it might be possible to relax or abolish price and profit controls on branded prescription medicines in the UK. [ + ]
Agenix appoints new US vet distributor
Brisbane-based Agenix (ASX:AGX) has appointed a new distributor for its animal health diagnostic products in the US. [ + ]
Arthritis CRC picks up new funding and partners
The Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs. [ + ]
Compumedics revenues, losses up
Compumedics' (ASX:CMP) revenues for the 2002-2003 financial year were up 62 per cent to AUD$32 million, reflecting strong growth in the company's sleep diagnostics business. [ + ]
Anadis therapy aiming to ease travellers' paths
It's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip. [ + ]
Patent could lead to new royalty revenue: CSL
A new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US. [ + ]
Do you have hyperactive platelets?
A researcher at the University of Newcastle is looking for patients with type-2 diabetes who are currently not taking anti-platelet medication for a new study involving tomato juice and fish oil!
[ + ]PanBio tips profit for 2003-04
Queensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today. [ + ]
AustCancer finds cancer jammer molecule
Perth-based cancer therapeutics developer Australian Cancer Technology's (ASX:ACU) joint discovery project with Cambridge-based BioFocus (AIM:BIO) has designed a tiny spanner to jam the molecular works of cancer cells that evade conventional chemotherapy and radiotherapy. [ + ]
Hunt for SARS source far from over: researcher
Virologists have some suspects, but the animal that originally hosted the lethal coronavirus that causes severe acute respiratory syndrome (SARS) in humans remains unidentified. [ + ]
New online publishing system boosts access to resources
In a boost for Australasian research, leading e-publisher RMIT Publishing has announced the release of a new online publishing and content management system to provide researchers with better access to a wide range of Australasian online resources currently available on its Informit Online service.
[ + ]S&P raises ResMed ratings
Standard & Poor's ratings services has raised its corporate credit rating on ResMed (ASX:RMD) to 'BB-' from 'B+', and raised its senior subordinated debt rating on the company to 'B' from 'B-'. [ + ]
Qld's Élan joins with US Meditech on biohazard
Queensland company Élan BioDynamics, a wholly owned subsidiary of the Élan Group, has entered a joint venture with US company Meditech Pharmaceuticals to commercialise a system for detection of biological hazards including aflatoxin, and anthrax. [ + ]
Pest solution goes back for mouse-to-mouse resuscitation
Plans to conduct the first contained field trial of a transgenic virus designed to prevent episodic plagues of the house mouse in the Australian wheat belt have been set back while researchers work to improve its transmission under field conditions [ + ]
CogState ponders market options
Unlisted Melbourne company CogState is contemplating a float on the Australian Stock Exchange, according to CEO Dr Peter Bick. [ + ]
